Filing Flows › Alkermes (ALKS) › Q2 2026 › vs Q1 2026
Alkermes (ALKS) Q2 2026 vs Q1 2026 (quarter over quarter)
Alkermes's revenue rose $103M (+26%) from $393M in Q1 2026 to $496M in Q2 2026. The biggest changes: Product +$73.6M (+22%); Manufactured Product and Royalty +$29.5M (+54%).
Alkermes, Q2 2026: revenue $496M (+27% year over year), operating margin 3.7%, net earnings $501K, operating cash flow $145M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 27.6% | -43.2% | +70.9 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Vivitrol | $124M | $112M | $12.0M | +11% |
| Aristada and Aristada Initio | $96.7M | $93.8M | $2.9M | +3% |
| LUMRYZ | $96.6M | $39.5M | $57.1M | +145% |
| LYBALVI | $94.0M | $92.4M | $1.6M | +2% |
| Royalty | $63.4M | $50.7M | $12.7M | +25% |
| Manufacturing Revenue | $20.9M | $4.1M | $16.8M | +414% |
| Product | $412M | $338M | $73.6M | +22% |
| Manufactured Product and Royalty | $84.3M | $54.8M | $29.5M | +54% |
| Revenue | $496M | $393M | $103M | +26% |
| Income tax benefit | $2.4M | −$4.6M | $6.9M | — |
| Costs & expenses | $498M | $459M | $39.0M | +8% |
| Operating costs | $478M | $441M | $36.5M | +8% |
| Interest & other, net | $20.2M | $13.6M | $6.6M | +48% |
| Net earnings | $501K | −$66.5M | $67.0M | — |
| Cost of revenue | $98.1M | $61.6M | $36.5M | +59% |
| Research & development | $113M | $103M | $9.6M | +9% |
| Sales & marketing | $154M | $156M | −$1.2M | -0.8% |
| General & admin | $63.3M | $109M | −$45.8M | -42% |
| Other operating costs | $49.0M | $11.7M | $37.3M | +320% |
| Operating cash sources | $145M | −$166M | $311M | — |
| Depreciation & amortization | $30.3M | $19.4M | $10.8M | +56% |
| Share-based compensation | $31.1M | $36.3M | −$5.2M | -14% |
| Working capital & other | $83.3M | −$155M | $238M | — |
| Operating cash flow | $145M | −$166M | $311M | — |
| Free cash flow (OCF − capex) | $137M | −$170M | $307M | — |
| Capital expenditures | $8.1M | $4.1M | $4.1M | +99% |
Questions
How much did Alkermes's revenue grow quarter over quarter in Q2 2026?
Alkermes's revenue rose $103M (+26%) from $393M in Q1 2026 to $496M in Q2 2026.
What drove Alkermes's revenue change in Q2 2026?
Product +$73.6M (+22%); Manufactured Product and Royalty +$29.5M (+54%).